Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Attitudes and Unmet Needs Among Type 2 Diabetes Patients
- Conditions
- Type 2 Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 700
- Registration Number
- NCT05737810
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT05727644
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 210
- Registration Number
- NCT05726227
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇩🇪Auf der Bult - Klinik für Diabetologie, Endokrinologie, Gastroenterologie und Klinische Forschung, Hannover, Germany
🇩🇪Universitätsklinikum Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin, Leipzig, Germany
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
- Conditions
- SGAISSNoonan SyndromeTurner Syndrome
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT05723835
- Locations
- 🇺🇸
Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States
🇺🇸Childrens National Medical Ctr, Washington, District of Columbia, United States
🇺🇸Rocky Mt Clin Res, LLC, Idaho Falls, Idaho, United States
A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 267
- Registration Number
- NCT05721989
- Locations
- 🇳🇱
ICON - location Groningen, Groningen, Netherlands
🇭🇺ICON Budapest Phase I Unit, Budapest, Hungary
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 288
- Registration Number
- NCT05716724
- Locations
- 🇰🇼
KOC Hospital, Ahmadi, Kuwait
🇸🇦Al Hammadi, Riyadh, Saudi Arabia
🇸🇦Dallah Hospital_Riyadh, Riyadh, Saudi Arabia
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
- Conditions
- Adult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT05718570
- Locations
- 🇺🇸
Stanford Univ School of Med, Palo Alto, California, United States
🇯🇵Kagoshima University Hospital_Neurosurgery, Kagoshima-shi, Kagoshima, Japan
🇺🇸St Lukes Physician Group, Center Valley, Pennsylvania, United States
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05714683
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05689372
Awareness, Care & Treatment In Obesity Management
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1688
- Registration Number
- NCT05690789
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Puteaux, France